A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects With MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function

Trial Profile

A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects With MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Tepotinib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 02 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Sep 2017 Final results of the phase Ib part (n=27) presented at the 42nd European Society for Medical Oncology Congress
    • 30 Aug 2017 Planned number of patients changed from 158 to 90.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top